In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 11 to 20 of 96

Sort by

Keyword or reference number: in`Remove $Keyword or reference number: in filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)	Health technology evaluation	2 December 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]	Technology appraisal guidance	30 September 2026
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]	Technology appraisal guidance	28 July 2021
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]	Technology appraisal guidance	24 February 2027
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]	Technology appraisal guidance	TBC

Results per page

10
25
50
All